HRA002175
Title:
Neoadjuvant camrelizumab plus apatinib for locally advanced resectable oral squamous cell carcinoma
Release date:
2022-03-28
Description:
Novel neoadjuvant therapy regimens are needed to improve the outcomes of patients with locally advanced resectable oral squamous cell carcinoma. Our findings demonstrate that neoadjuvant therapy with a combination of camrelizumab and apatinib is safe and yields a promising MPR rate
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cohort Study
Disease name:
oral squamous cell carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Laiping Zhong' Research team
Contact person:
Zhong Lai-ping
Email:
zhonglp@hotmail.com
Description:
Laiping Zhong' Research team
Individuals & samples
Submitter:   Zhong Lai-ping / zhonglp@hotmail.com
Organization:   Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Submission date:   2022-03-28
Requests:   -